SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose regimen of SB-715992 in combination with
docetaxel in patients with solid tumors. SB-715992 and docetaxel were dosed by 1-hour
intravenous infusion every 3 weeks (on the same day). A patient may continue to receive
treatment as long as they are benefiting from the treatment. Blood samples will be taken at
specific times to measure the amount of both drugs in your body at specific times after the
drug is given. Blood samples will also be taken for lab tests such as complete blood counts
and clinical chemistries. Physical exams will be performed before each treatment with
SB-715992. During the treatment phase, the patients will undergo regular assessments for
safety and clinical response.